Enzybiotics: A look to the future, recalling the past

Journal of Pharmaceutical Sciences

Volumn 96, Issue 8, 2007, Pages 1917-1924

  Veiga Crespo, Patricia ^a   Ageitos, José Manuel ^a   Poza, Margarita ^a   Villa, Tomás G ^a  

^a Pharmacy Faculty   (Spain)

Author keywords

Antibiotic; Biotechnology; Drug resistance; Drug therapy; Enzybiotic; Enzyme; Microorganism; Phage; Protein; Protein binding

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; CLOTRIMAZOLE; CYCLOSPORIN; ENZYBIOTIC DERIVATIVE; FLUCONAZOLE; GENTAMICIN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NUCLEOSIDE ANALOG; NYSTATIN; PENICILLIN G; PROTEIN CPL 1; PROTEIN LYSIN C1; PROTEIN LYSIN PLYG; PROTEIN LYSIN PSI13; PROTEIN LYSIN PSI6; PROTEIN LYSINE ENB6; PROTEIN P17; PROTEIN PAL; PROTEIN PLYGBS; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ALLERGY; BACTERIAL INFECTION; BACTERIOLYSIS; BACTERIOPHAGE; BURN; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG DOSE INCREASE; DRUG INDUSTRY; DRUG POTENTIATION; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; INTESTINE INFECTION; KIDNEY DISEASE; LIVER TOXICITY; MYCOSIS; NONHUMAN; NOSE INFECTION; PHARYNGITIS; PHLEBITIS; PROTEIN EXPRESSION; REVIEW; SHIGELLOSIS; SINGLE DRUG DOSE; SKIN INFECTION; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS INFECTION; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

EID: 34548016989     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20853     Document Type: Review

References (54)

1. Madigan MT, Martiko JM, Parker J. 2004. Brock. Biologia de los Microorganismos. 10th Ed. Madrid: Pearson Educacion.
2. Sulakvelidze A, Alavidze Z, Jr., Morris JG. 2001. Bacteriophage therapy. Antimicrob Agents Chemother 45:649-659.
3. Twort FW. 1915. An investigation on the nature of ultramicroscopic viruses. Lancet ii:1241.
4. D'Herelle F. 1917. Sur un microbe invisible antagoniste des bacilles dysentériques. CR Acad Sci 165:373-375.
5. Duckworth DH. 1976. Who discovered bacteriophage? Bacteriol Rev 40:793-802.
6. Fischetti VA. 2005. Bacteriophage lytic enzymes: Novel anti-infectives. Trends Microbiol 13:491-496.
7. Cheng Q, Nelson D, Zhu S, Fischetti VA. 2005. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemoth 49:111-117.
8. Lopez R, Garcia E, Garcia P, Garcia JL. 1997. The pneumococcal cell wall degrading enzymes: A modular design to create new lysins? Microb Drug Resist 3:199-211.
9. Nakimbugwe D, Masschalck B, Atanassova M, Zewdie-Bosuner A, Michiels CW. 2006. Comparison of bactericidal activity of six lysozymes at atmospheric pressure and under high hydrostatic pressure. Int J Food Microbiol 108:355-363.
10. Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P. 2003. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. JAC 52:967-973.
11. Hermoso JA, Monterroso B, Albert A, Galan B, Ahrazen O, Garcia P, Martinez-Ripoll M, Garcia JL, Menendez M. 2003. Structural basis for selective recognition of pneumococcal cell wall by modular endolysin from phage Cp-1. Structure 11:1239-1249.
12. Wang IN, Smith DL, Young R. 2000. Holins: The protein clocks of bacteriophage infections. Ann Rev Microbiol 54:799-825.
13. Young I, Wang I, Roof WD. 2000. Phages will out: Strategies of host cell lysis. Trends Microbiol 8:120-128.
14. Smith DL, Struck DK, Scholtz JM, Young R. 1998. Purification and biochemical characterization of the lambda Holin. J Bacteriol 180:2531-2540.
15. Grundling A, Smith DL, Blasi U, Young R. 2000. Dimerization between the Holin and Holin inhibitor of phage lambda. J Bacteriol 182:6075-6081.
16. Summers WC. 1999. Felix d'Herelle and the origins of molecular biology. 1st Ed. New Haven: Yale University Press.
17. Bruynoghe R, Maisin J. 1921. Essais de therapeutique au moyem du bactériophage. CR Soc Biol 85:1120-1121.
18. Sulakvelidze A. 2005. Phage therapy: An attractive option for dealing with antibiotic-resistant bacterial infections. Drugs Discov Today 12:807-809.
19. Nelson D, Loomis L, Fischetti VA. 2001. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. PNAS 98:4107-4112.
20. Ronda C, Vazquez M, Lopez R. 2003. Los bacteriofagos como herramienta para combatir infecciones en Acuicultura. AquaTic 18:3-10.
21. Dixon B. 2004. New dawn for phage therapy, Lancet Infect Dis 4:186. Antes la 28.
22. Schuch R, Nelson D, Fischetti VA. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-889.
23. Hagens S, Blasi U. 2003. Genetically modified filamentous phage as bactericidal agents: A pilot study. Lett Appl Microbiol 37:318-323.
24. Westwater C, Kasman LM, Schofield DA, Werner PA, Dolan JW, Schmidt MG, Morris JS. 2003. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: An alternative therapy for treatment of bacterial infections. Antimicrob Agents Chemother 47:1301-1307.
25. Morris JS, Westwater C, Schofield D. 2000. Prokaryotic gene therapy to combat multidrug resistant bacterial infection. Gene Ther 7:723-725.
26. Projan S. 2004. Phage-inspired antibiotics? Nat Biotechnol 22:506-507.
27. Biswas B, Adhya S, Washart P, Paul B, Trostel AN, Powell B, Carlton R, Merril CR. 2002. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect Immun 70:204-210.
28. Takac M, Blasi U. 2005. Phage P68 virion-associated protein 17 displays activity against clinical isolates of Staphylococcus aureus. Antimicrob Agents Chemother 49:2934-2940.
29. Loeffler JM, Fischetti VA. 2003. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 47:375-377.
30. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172.
31. Dangelavicius R, Cvirkarte V, Gaidelyte A, Bakiene E, Gabrenaite-Verkhovskaya R, Bamford DH. 2005. Penetration of enveloped double-stranded RNA bacteriophages φ13 and φ6 into Pseudomonas syringae cells. J Virol 79:5017-5026.
32. Klis FM, Boorsma A, De Groot PW. 2006. Cell wall construction in Saccharomyces cerevisiae. Yeast 23:185-202.
33. Adams DJ. 2004. Fungal cell wall chitinases and glucanases. Microbiology 150:2029-2035.
34. www.medicinenet.com.
35. www.rxlist.com.
36. www.nlm.nih.gov/medlineplus/druginformation.html.
37. Block ER, Bennet JE. 1972. Pharmacological studies with 5-Fluorocytosine. Antimicrob Agents Chemother 1:476-482.
38. www.hpb.gov.sg/hpb/default.asp?pg_id=865&aid=237.
39. www.drugsafetysite.com.
40. www.doctorfungus.org/thedrugs/medical.htm.
41. Sinnot ML. 1990. Catalytic mechanisms of enzymic glycosyl transfer. Chem Rew 90:1171-1202.
42. Ring M, Bader DE, Hubber M. 1988. Site-directed mutagenesis of beta-galactosidase (E. coli) reveals that tyr-503 is essential for activity. Biochem Biophys Res Com 152:1050-1055.
43. www.expasy.ch/cig-bin/lists?glycosid.txt.
44. Kawai R, Igarashi K, Samejima M. 2006. Gene cloning and heterologous expression of glycoside hydrolase family 55 beta-1,3-glucanase from the basidiomycete Phanerochaete chrysosporium. Biotechnol Lett 28:365-371.
45. Coenen TMM, Schoenmakers ACM, Verhagen H. 1995. Safety evaluation of β-glucanase derived from Trichoderma reesei: Summary of toxilogical data. Food Chem 95:859-866.
46. Herrero AB, Magnelli P, Mansour M, Levitz SM, Bussey H, Abeijon C. 2004. KRE5 gene null mutant strains of Candida albicans are avirulent and have altered cell wall composition and hypha formation properties. Eukaryotic Cell 3:1423-1432.
47. Elias JA, Homer RJ, Hamid Q, Lee CG. 2005. Chitinases and chitinase-like proteins in T(H)2 inflammation and asthma. J Allergy Clin Immunol 116:497-500.
48. Boot RG, Blonmaart EF, Swart E, van der Vlugt KG, Bijl N, Moe C. 2001. Identification of a novel acidic mammalian chitinase distinct from chitotriosidase. J Biol Chem 276:6770-6778.
49. Dahiya N, Tewari R, Hoondal GS. 2005. Biotechnological aspects of chitinolytic enzymes: a review. Appl Microbiol Biotechnol Onlinefirst 1-10.
50. Pope A, Davis D. 1979. The influence of carbohydrates on the growth of fungal pathogens in vitro and in vivo. Postgrad Med J 55:674-676.
51. Howard MB, Ekborg NA, Weiner RM, Hutcheson SW. 2003. Detection and characterization of chitinases and other chitin modifying enzymes. J Ind Microbiol Biotechnol 30:627-635.
52. Felt O, Buri P, Gurny R. 1998. Chitosan: A unique polysaccharide for drug delivery. Drug Dev Ind Pharm 24:979-993.
53. Drozd N, Sher A, Makarov V, Galbraikh L, Vikhoreva G, Gorbachiova I. 2001. Comparison of antithrombin activity of the polysulphate chitosan derivatives in in vivo and in vitro system. Thromb Res 102:445-455.
54. Singla A, Chawla M. 2001. Chitosan: Some pharmaceutical and biological aspects-an update. J Pharm Pharmacol 53:1047-1067.